{"url_path":"/sec/ntla/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-270358-index.html","accession_number":"0001193125-26-270358","cik":"0001652130","ticker":"NTLA","issuer_name":"Intellia Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1652130/0001193125-26-270358-index.html","primary_entity_key":"0001652130","primary_entity_name":"Intellia Therapeutics, Inc."},"word_count":101,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNo.\n\n \n\n \n\nDescription\n\n \n\n \n\n \n\n 99.1\n\n \n\n[Press release dated June 13, 2026 titled “Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema.”](ntla-ex99_1.htm)\n\n \n\n \n\n \n\n 104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\nIntellia Therapeutics, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 15, 2026\n\nBy:\n\n/s/ John M. Leonard\n\n \n\n \n\n \n\nName: John M. Leonard\nTitle: Chief Executive Officer and President"}